Classification of Ph-negative chronic myeloproliferative disorders - Morphology as the yardstick of classification

被引:13
|
作者
Kvasnicka, Hans Michael [1 ]
Thiele, Juergen [1 ]
机构
[1] Univ Cologne, Inst Pathol, DE-50924 Cologne, Germany
关键词
bone marrow histology; chronic myeloproliferative disorders; polycythemia vera; chronic idiopathic myelofibrosis; essential thrombocythemia;
D O I
10.1159/000101706
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: Histopathology of bone marrow ( BM) biopsies plays a crucial role in the interdisciplinary approach to diagnosis and classification of Ph-negative chronic myeloproliferative disorders. Based on careful clinicopathologic studies, BM features are critical determinants that help to predict overall prognosis, to detect complications such as progression to myelofibrosis and blast crisis, and to assess therapy-related changes. Methods and Results: A systematic evaluation of BM histopathology allows an objective identification of cases of ( true) essential thrombocythemia and their separation from early prefibrotic stages of chronic idiopathic myelofibrosis. By follow-up examinations that include BM biopsies, the progression of the disease process is unveiled, which is especially important for patients with initial polycythemia vera and prefibrotic chronic idiopathic myelofibrosis that may require a different therapeutic approach than the full-blown stages. Conclusion: BM biopsy should be considered as major diagnostic tool for evaluation and follow-up of patients enrolled in prospective studies. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:63 / 71
页数:9
相关论文
共 50 条
  • [1] Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
    Spanoudakis, Emmanouil
    Tsatalas, Costas
    [J]. CURRENT STEM CELL RESEARCH & THERAPY, 2009, 4 (02) : 154 - 160
  • [2] Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies
    Georgii, A
    Buhr, T
    Buesche, G
    Kreft, A
    Choritz, H
    [J]. LEUKEMIA & LYMPHOMA, 1996, 22 : 15 - 29
  • [3] The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders
    Hasselbalch, Hans Carl
    Riley, Caroline H.
    [J]. CURRENT DRUG TARGETS, 2007, 8 (02) : 247 - 256
  • [4] BIOPHISICAL PROPERTIES OF PLATELET MEMBRANE IN PATIENTS WITH PH-NEGATIVE CHRONIC MYELOPROLIFERATIVE DISORDERS
    Popov, V. M.
    Vladareanu, A. M.
    Bumbea, H.
    Nicolescu, A.
    Onisai, M.
    Eugenia, K.
    Savopol, T.
    Moisescu, M.
    Iordache, M.
    Mihai, C.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 599 - 599
  • [5] Ischemic stroke in the setting of PH-negative myeloproliferative disorders
    Kuznetsova, P.
    Raskurazhev, A.
    Medvedev, R.
    Lagoda, O.
    Shabalina, A.
    Tanashyan, M.
    [J]. CEREBROVASCULAR DISEASES, 2017, 43
  • [6] Thrombotic complications in the setting of PH-negative myeloproliferative disorders
    Kuznetsova, P.
    Raskurazhev, A.
    Medvedev, R.
    Lagoda, O.
    Shabalina, A.
    Tanashyan, M.
    [J]. CEREBROVASCULAR DISEASES, 2017, 43
  • [7] GENETIC HETEROGENEITY OF PH-NEGATIVE CHRONIC MYELOPROLIFERATIVE DISEASES
    Aleksandrova, T. N.
    Pavlova, N., I
    Kurtanov, Kh A.
    Mulina, I. I.
    Yadrikhinskaya, V. N.
    [J]. YAKUT MEDICAL JOURNAL, 2019, (01): : 88 - 91
  • [8] THE INCIDENCE OF Ph-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS IN BELARUS
    Martinkov, V. N.
    Novik, D. K.
    Veyalkin, I. V.
    Silin, A. E.
    Iskrov, I. A.
    [J]. GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2023, 68 (03): : 363 - 372
  • [9] FOCAL BRAIN CHANGES IN THE SETTING OF PH-NEGATIVE MYELOPROLIFERATIVE DISORDERS
    Kuznetsova, P.
    Raskurazhev, A.
    Tanashyan, M.
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 498 - 498
  • [10] Brain MRI-findings in Ph-negative myeloproliferative disorders
    Tanashyan, M. M.
    Melikyan, A. L.
    Kuznetsova, P., I
    Raskurazhev, A. A.
    Shabalina, A. A.
    Konovalov, R. N.
    [J]. TERAPEVTICHESKII ARKHIV, 2019, 91 (07): : 29 - 34